secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2023-06-15T23:59:59+00:00
Accession:  0001104659-23-071602
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MedTech Acquisition (MTAC) extends deadline to Sept 22; 808,628 shares redeemed
-------------------------------------------------------------------------------

- Stockholders approved extension of business combination deadline from June 22 to Sept 22, 2023, plus related charter amendments.
- 808,628 public shares redeemed at ~$10.49/share; ~$8.48M removed from trust, leaving ~$12M.
- Sponsor issued promissory note for up to $137,375.28 (0% interest) to fund monthly extension deposits into trust.
- Post-redemption: 1,144,794 public shares outstanding; $45,791.76/month deposit split 50/50 between note and TriSalus.
- Charter amendments allow founder share conversion at any time pre-closing and eliminate $5M net tangible asset redemption limit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000110465923071602/0001104659-23-071602-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000110465923071602/tm2318652d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-071602

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer